Elicera Therapeutics AB (publ) (STO:ELIC)

Sweden · Delayed Price · Currency is SEK

3.280

+0.065 (2.02%)

Apr 29, 2026, 9:24 AM CET

-24.60% (1Y)

Market Cap	156.04M
Revenue (ttm)	10.64M
Net Income (ttm)	-14.45M
Shares Out	48.54M
EPS (ttm)	-0.30
PE Ratio	n/a
Forward PE	21.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,865
Average Volume	182,311
Open	3.235
Previous Close	3.215
Day's Range	3.235 - 3.285
52-Week Range	3.060 - 8.430
Beta	0.55
RSI	19.56
Earnings Date	May 5, 2026

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 2

Stock Exchange Nasdaq Stockholm

Ticker Symbol ELIC

Full Company Profile

Financial Performance

In 2025, Elicera Therapeutics AB's revenue was 10.86 million, an increase of 52.28% compared to the previous year's 7.13 million. Losses were -17.41 million, 8.05% more than in 2024.

Financial Statements

News

Elicera Therapeutics AB Transcript: Investor Update

Promising early clinical results were reported for the lead CAR-T program, with a complete response in the first patient and mild side effects. The company secured funding to support operations through 2027, expects multiple clinical data readouts in 2025, and is pursuing partnerships and licensing for its ITANK platform.

1 year ago - Transcripts